Filtered By:
Cancer: Myeloma

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 82 results found since Jan 2013.

Multiple Myeloma Stage I, II and Renal Insufficiency Are Associated with Increased Stroke Risk (S31.003)
Conclusion: In multiple myeloma,patient’s renal insufficiency and MM Stage I and II were independent predictors of increased stroke risk. Besides these hypercoagulability, atrial fibrillation, watershed strokes and small vessel disease played important role.Disclosure: Dr. Limaye has nothing to disclose. Dr. Ravilla has nothing to disclose. Dr. Appalnaidu has nothing to disclose. Dr. Papanikolaou has nothing to disclose. Dr. Waheed has nothing to disclose. Dr. Hinduja has nothing to disclose.
Source: Neurology - February 7, 2016 Category: Neurology Authors: Limaye, K., Ravilla, R., Sasapu, A., Papanikolaou, X., Waheed, S., Hinduja, A. Tags: Stroke Risk, Outcomes, and Complications Source Type: research

Acute Ischemic Stroke as a Presenting Feature of Multiple Myeloma (P3.279)
Conclusions:Stroke is a leading and preventable cause of disability in the US adult population. The majority of strokes are due to atherosclerotic vascular or cardioembolic disease. Understanding the diagnostic work up of stroke and recognizing rare etiologies like MM is important for stroke prevention. This brings to light the importance of recognizing stroke as an initial presenting feature of multiple myeloma and of multiple myeloma as an important treatable etiology of stroke.Disclosure: Dr. Chung has nothing to disclose. Dr. Ramamoorthy has nothing to disclose. Dr. Kar has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Chung, S., Ramamoorthy, R., Kar, J. Tags: Cerebrovascular Disease Case Reports II Source Type: research

Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study
This study includes consecutive patients 20 years and older who were newly diagnosed with symptomatic multiple myeloma at Taipei Veterans General Hospital, a tertiary medical center, between January 1, 2002 and December 31, 2014. The primary outcome was stroke development. Patients with head injuries, brain tumors, brain parenchymal invasions, or antecedent malignancies were excluded. Hazard ratios (HRs) of stroke risk factors for multiple myeloma patients were estimated by Cox proportional regression analysis. Overall, 395 patients with a median age of 70 years were investigated. In the median follow‐up period of 18 ...
Source: Hematological Oncology - August 21, 2016 Category: Hematology Authors: Gin ‐Yi Lee, Yu‐Ting Lee, Chiu‐Mei Yeh, Pei Hsu, Ting‐Wei Lin, Jyh‐Pyng Gau, Yuan‐Bin Yu, Liang‐Tsai Hsiao, Cheng‐Hwai Tzeng, Tzeon‐Jye Chiou, Jin‐Hwang Liu, Yao‐Chung Liu, Chia‐Jen Liu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Conclusions Patients with AML have an elevated risk of CVA compared to all inpatients and mortality in this population is high. Better characterization of risk factors of stroke in this vulnerable population is still needed. Teaser Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke i...
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research

Is stroke incidence increased in survivors of adult cancers? A systematic review and meta-analysis
ConclusionsStroke incidence is significantly increased after diagnosis of certain cancers.Implications for Cancer SurvivorsCardiovascular risk should be assessed during cancer survivorship care, with attention to modifying shared cancer/cardiovascular risk factors.
Source: Journal of Cancer Survivorship - November 5, 2021 Category: Cancer & Oncology Source Type: research

Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
CONCLUSION: This study highlights that elevated baseline AF/stroke-related risk does not adversely impact TTD and TTNT outcomes associated with ibrutinib use. Additionally, TTNT was significantly longer for patients treated with ibrutinib vs. other regimens.PMID:35973891 | DOI:10.1016/j.clml.2022.07.004
Source: Clinical Lymphoma and Myeloma - August 16, 2022 Category: Cancer & Oncology Authors: Anna Narezkina Nausheen Akhter Xiaoxiao Lu Bruno Emond Sumeet Panjabi Shaun P Forbes Annalise Hilts Stephanie Liu Marie-H élène Lafeuille Patrick Lefebvre Qing Huang Michael Choi Source Type: research

Increased Risk of Ischemic Stroke in Multiple Myeloma Associated With Lenalidomide Treatment: A Case Report and Review of the Literature
Conclusions Our case exemplifies the need to raise awareness about the risk of ischemic stroke associated with MM that might be increased by treatment with lenalidomide and to establish consistent recommendations regarding thromboprophylaxis to reduce comorbidities and mortality in these patients.
Source: Clinical Neuropharmacology - November 1, 2018 Category: Neurology Tags: Case Reports Source Type: research

Pseudo-stroke manifestation of multiple myeloma: a report of two cases with literature review.
We describe two patients with pseudo-stroke manifestation of multiple myeloma. The first patient was a 60-year-old female with the initial presentation of multiple myeloma forming a large skull tumour compressing the brain with resultant symptoms of aphasia, limited logical contact and right upper extremity paresis. The second patient was a 69-year-old female who presented with a partial motor epileptic seizure involving both right limbs with persisting weakness of muscles and speech disturbances due to a skull tumour 4 years after the diagnosis of multiple myeloma. Pseudo-stroke manifestation of multiple myeloma is extrem...
Source: Folia Neuropathologica - May 26, 2013 Category: Pathology Authors: Czapiewski P, Szmuda T, Dzierżanowski J, Słoniewski P, Sworczak K, Gnacińska M, Dubaniewicz-Wybieralska M, Hellmann A, Biernat W Tags: Folia Neuropathol Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke included UTI, hypernatremia and acute renal failure.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Christopher Del Prete, Taeha Kim, Frederick Lansigan, Joseph Shatzel, Harley Friedman Source Type: research

Real-World Persistence and Time to Next Treatment with Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF/stroke risk remain unknown.
Source: Clinical Lymphoma, Myeloma and Leukemia - July 12, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Sumeet Panjabi, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-H élène Lafeuille, Patrick Lefebvre, Qing Huang, Michael Choi Tags: Original Study Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cerebrovascular manifestations in hematological diseases: an update
AbstractPatients with hematological diseases often experience cerebrovascular complications including ischemic stroke, intracerebral and subarachnoid hemorrhage, microbleeds, posterior reversible encephalopathy syndrome, and dural sinus and cerebral vein thrombosis (CVT). In this update, we will review recent advances in the management of cerebrovascular diseases in the context of myeloproliferative neoplasms, leukemias, lymphomas, multiple myeloma, POEMS, paroxysmal nocturnal hemoglobinuria (PNH), thrombotic thrombocytopenic purpura (TTP), and sickle-cell disease. In acute ischemic stroke associated with hematological dis...
Source: Journal of Neurology - February 13, 2021 Category: Neurology Source Type: research